nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—CYP3A5—Rosuvastatin—atherosclerosis	0.0502	0.0771	CbGbCtD
Lapatinib—CYP3A5—Simvastatin—atherosclerosis	0.0467	0.0716	CbGbCtD
Lapatinib—CYP3A5—Lovastatin—atherosclerosis	0.0457	0.0701	CbGbCtD
Lapatinib—CYP3A5—Pravastatin—atherosclerosis	0.0457	0.0701	CbGbCtD
Lapatinib—CYP2C8—Simvastatin—atherosclerosis	0.0449	0.0689	CbGbCtD
Lapatinib—CYP2C8—Lovastatin—atherosclerosis	0.0439	0.0674	CbGbCtD
Lapatinib—CYP2C8—Pravastatin—atherosclerosis	0.0439	0.0674	CbGbCtD
Lapatinib—CYP2C19—Rosuvastatin—atherosclerosis	0.0405	0.0622	CbGbCtD
Lapatinib—CYP2C19—Simvastatin—atherosclerosis	0.0376	0.0578	CbGbCtD
Lapatinib—CYP2C19—Lovastatin—atherosclerosis	0.0368	0.0565	CbGbCtD
Lapatinib—ABCB1—Ezetimibe—atherosclerosis	0.0327	0.0501	CbGbCtD
Lapatinib—ABCB1—Simvastatin—atherosclerosis	0.0304	0.0466	CbGbCtD
Lapatinib—ABCB1—Pravastatin—atherosclerosis	0.0297	0.0456	CbGbCtD
Lapatinib—ABCB1—Lovastatin—atherosclerosis	0.0297	0.0456	CbGbCtD
Lapatinib—CYP3A4—Rosuvastatin—atherosclerosis	0.0196	0.03	CbGbCtD
Lapatinib—CYP3A4—Ezetimibe—atherosclerosis	0.0196	0.03	CbGbCtD
Lapatinib—CYP3A4—Simvastatin—atherosclerosis	0.0182	0.0279	CbGbCtD
Lapatinib—CYP3A4—Pravastatin—atherosclerosis	0.0178	0.0273	CbGbCtD
Lapatinib—CYP3A4—Lovastatin—atherosclerosis	0.0178	0.0273	CbGbCtD
Lapatinib—Blood disorder—Rosuvastatin—atherosclerosis	0.00279	0.0194	CcSEcCtD
Lapatinib—Interstitial lung disease—Ezetimibe—atherosclerosis	0.00273	0.019	CcSEcCtD
Lapatinib—Interstitial lung disease—Simvastatin—atherosclerosis	0.00261	0.0181	CcSEcCtD
Lapatinib—Interstitial lung disease—Pravastatin—atherosclerosis	0.00236	0.0164	CcSEcCtD
Lapatinib—Neoplasm malignant—Ezetimibe—atherosclerosis	0.00227	0.0158	CcSEcCtD
Lapatinib—Hepatotoxicity—Niacin—atherosclerosis	0.0022	0.0153	CcSEcCtD
Lapatinib—TAP1—adipose tissue—atherosclerosis	0.00216	0.0885	CbGeAlD
Lapatinib—ERBB2—connective tissue—atherosclerosis	0.00206	0.0842	CbGeAlD
Lapatinib—PIK3C2B—adipose tissue—atherosclerosis	0.00203	0.083	CbGeAlD
Lapatinib—Hyperbilirubinaemia—Niacin—atherosclerosis	0.00186	0.013	CcSEcCtD
Lapatinib—Renal failure acute—Rosuvastatin—atherosclerosis	0.00183	0.0127	CcSEcCtD
Lapatinib—ERBB2—cardiovascular system—atherosclerosis	0.00179	0.0732	CbGeAlD
Lapatinib—ERBB4—cardiovascular system—atherosclerosis	0.00179	0.0732	CbGeAlD
Lapatinib—ERBB2—adipose tissue—atherosclerosis	0.00158	0.0646	CbGeAlD
Lapatinib—ERBB4—adipose tissue—atherosclerosis	0.00158	0.0646	CbGeAlD
Lapatinib—TAP1—liver—atherosclerosis	0.00152	0.062	CbGeAlD
Lapatinib—Hot flush—Ezetimibe—atherosclerosis	0.0015	0.0104	CcSEcCtD
Lapatinib—Menopausal symptoms—Ezetimibe—atherosclerosis	0.00149	0.0103	CcSEcCtD
Lapatinib—PI4KB—adipose tissue—atherosclerosis	0.00148	0.0605	CbGeAlD
Lapatinib—Pain in extremity—Lovastatin—atherosclerosis	0.00143	0.00995	CcSEcCtD
Lapatinib—PIK3C2B—liver—atherosclerosis	0.00142	0.0582	CbGeAlD
Lapatinib—Pain in extremity—Ezetimibe—atherosclerosis	0.00141	0.00976	CcSEcCtD
Lapatinib—EGFR—adipose tissue—atherosclerosis	0.00134	0.0548	CbGeAlD
Lapatinib—Renal failure acute—Pravastatin—atherosclerosis	0.00131	0.00912	CcSEcCtD
Lapatinib—Hot flush—Pravastatin—atherosclerosis	0.0013	0.009	CcSEcCtD
Lapatinib—Menopausal symptoms—Pravastatin—atherosclerosis	0.00128	0.00892	CcSEcCtD
Lapatinib—Neuropathy peripheral—Rosuvastatin—atherosclerosis	0.00128	0.00887	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.00124	0.00861	CcSEcCtD
Lapatinib—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.00123	0.00856	CcSEcCtD
Lapatinib—Dry skin—Niacin—atherosclerosis	0.00113	0.00784	CcSEcCtD
Lapatinib—Dry skin—Pravastatin—atherosclerosis	0.00111	0.00772	CcSEcCtD
Lapatinib—ERBB2—liver—atherosclerosis	0.00111	0.0453	CbGeAlD
Lapatinib—Infestation—Ezetimibe—atherosclerosis	0.00108	0.00752	CcSEcCtD
Lapatinib—Infestation NOS—Ezetimibe—atherosclerosis	0.00108	0.00752	CcSEcCtD
Lapatinib—Neuropathy peripheral—Lovastatin—atherosclerosis	0.00108	0.00752	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.00107	0.00742	CcSEcCtD
Lapatinib—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.00106	0.00737	CcSEcCtD
Lapatinib—PI4KB—liver—atherosclerosis	0.00104	0.0424	CbGeAlD
Lapatinib—Mental disorder—Rosuvastatin—atherosclerosis	0.00102	0.00712	CcSEcCtD
Lapatinib—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.00102	0.00712	CcSEcCtD
Lapatinib—Neuropathy peripheral—Simvastatin—atherosclerosis	0.00101	0.00703	CcSEcCtD
Lapatinib—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000955	0.00664	CcSEcCtD
Lapatinib—EGFR—liver—atherosclerosis	0.000938	0.0384	CbGeAlD
Lapatinib—Stomatitis—Niacin—atherosclerosis	0.000924	0.00642	CcSEcCtD
Lapatinib—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000915	0.00636	CcSEcCtD
Lapatinib—Cough—Rosuvastatin—atherosclerosis	0.000888	0.00617	CcSEcCtD
Lapatinib—Angiopathy—Ezetimibe—atherosclerosis	0.000882	0.00613	CcSEcCtD
Lapatinib—Immune system disorder—Ezetimibe—atherosclerosis	0.000878	0.0061	CcSEcCtD
Lapatinib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000876	0.00609	CcSEcCtD
Lapatinib—Alopecia—Lovastatin—atherosclerosis	0.000876	0.00608	CcSEcCtD
Lapatinib—Myalgia—Rosuvastatin—atherosclerosis	0.000867	0.00602	CcSEcCtD
Lapatinib—Arthralgia—Rosuvastatin—atherosclerosis	0.000867	0.00602	CcSEcCtD
Lapatinib—Alopecia—Ezetimibe—atherosclerosis	0.000859	0.00597	CcSEcCtD
Lapatinib—Mental disorder—Ezetimibe—atherosclerosis	0.000852	0.00592	CcSEcCtD
Lapatinib—Malnutrition—Ezetimibe—atherosclerosis	0.000846	0.00588	CcSEcCtD
Lapatinib—Back pain—Lovastatin—atherosclerosis	0.000835	0.0058	CcSEcCtD
Lapatinib—Infection—Rosuvastatin—atherosclerosis	0.000825	0.00574	CcSEcCtD
Lapatinib—Alopecia—Simvastatin—atherosclerosis	0.000819	0.00569	CcSEcCtD
Lapatinib—Back pain—Ezetimibe—atherosclerosis	0.000819	0.00569	CcSEcCtD
Lapatinib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000815	0.00566	CcSEcCtD
Lapatinib—Mental disorder—Simvastatin—atherosclerosis	0.000812	0.00564	CcSEcCtD
Lapatinib—Anaemia—Ezetimibe—atherosclerosis	0.000782	0.00543	CcSEcCtD
Lapatinib—Cardiac disorder—Pravastatin—atherosclerosis	0.000778	0.0054	CcSEcCtD
Lapatinib—Angiopathy—Niacin—atherosclerosis	0.000772	0.00537	CcSEcCtD
Lapatinib—Leukopenia—Lovastatin—atherosclerosis	0.000772	0.00537	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000757	0.00526	CcSEcCtD
Lapatinib—Alopecia—Niacin—atherosclerosis	0.000752	0.00523	CcSEcCtD
Lapatinib—Insomnia—Rosuvastatin—atherosclerosis	0.000751	0.00522	CcSEcCtD
Lapatinib—Palpitations—Ezetimibe—atherosclerosis	0.000748	0.0052	CcSEcCtD
Lapatinib—Anaemia—Simvastatin—atherosclerosis	0.000746	0.00518	CcSEcCtD
Lapatinib—Malnutrition—Niacin—atherosclerosis	0.000741	0.00515	CcSEcCtD
Lapatinib—Alopecia—Pravastatin—atherosclerosis	0.000741	0.00515	CcSEcCtD
Lapatinib—Cough—Ezetimibe—atherosclerosis	0.000738	0.00513	CcSEcCtD
Lapatinib—Arthralgia—Lovastatin—atherosclerosis	0.000735	0.0051	CcSEcCtD
Lapatinib—Myalgia—Lovastatin—atherosclerosis	0.000735	0.0051	CcSEcCtD
Lapatinib—Dyspepsia—Rosuvastatin—atherosclerosis	0.000731	0.00508	CcSEcCtD
Lapatinib—Leukopenia—Simvastatin—atherosclerosis	0.000722	0.00502	CcSEcCtD
Lapatinib—Myalgia—Ezetimibe—atherosclerosis	0.00072	0.00501	CcSEcCtD
Lapatinib—Arthralgia—Ezetimibe—atherosclerosis	0.00072	0.00501	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000715	0.00497	CcSEcCtD
Lapatinib—Constipation—Rosuvastatin—atherosclerosis	0.000711	0.00494	CcSEcCtD
Lapatinib—Anaphylactic shock—Lovastatin—atherosclerosis	0.000704	0.00489	CcSEcCtD
Lapatinib—Infection—Lovastatin—atherosclerosis	0.0007	0.00486	CcSEcCtD
Lapatinib—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000691	0.0048	CcSEcCtD
Lapatinib—Arthralgia—Simvastatin—atherosclerosis	0.000687	0.00477	CcSEcCtD
Lapatinib—Myalgia—Simvastatin—atherosclerosis	0.000687	0.00477	CcSEcCtD
Lapatinib—Infection—Ezetimibe—atherosclerosis	0.000686	0.00477	CcSEcCtD
Lapatinib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000679	0.00472	CcSEcCtD
Lapatinib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000677	0.00471	CcSEcCtD
Lapatinib—Anaemia—Pravastatin—atherosclerosis	0.000674	0.00469	CcSEcCtD
Lapatinib—Anorexia—Lovastatin—atherosclerosis	0.000671	0.00466	CcSEcCtD
Lapatinib—Skin disorder—Ezetimibe—atherosclerosis	0.000671	0.00466	CcSEcCtD
Lapatinib—Leukopenia—Niacin—atherosclerosis	0.000663	0.00461	CcSEcCtD
Lapatinib—Anaphylactic shock—Simvastatin—atherosclerosis	0.000659	0.00458	CcSEcCtD
Lapatinib—Abdominal pain—Rosuvastatin—atherosclerosis	0.000657	0.00456	CcSEcCtD
Lapatinib—Palpitations—Niacin—atherosclerosis	0.000655	0.00455	CcSEcCtD
Lapatinib—Infection—Simvastatin—atherosclerosis	0.000654	0.00455	CcSEcCtD
Lapatinib—Leukopenia—Pravastatin—atherosclerosis	0.000653	0.00454	CcSEcCtD
Lapatinib—Cough—Niacin—atherosclerosis	0.000647	0.00449	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000642	0.00446	CcSEcCtD
Lapatinib—Insomnia—Lovastatin—atherosclerosis	0.000637	0.00442	CcSEcCtD
Lapatinib—Cough—Pravastatin—atherosclerosis	0.000637	0.00442	CcSEcCtD
Lapatinib—Myalgia—Niacin—atherosclerosis	0.000631	0.00438	CcSEcCtD
Lapatinib—Arthralgia—Niacin—atherosclerosis	0.000631	0.00438	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000629	0.00437	CcSEcCtD
Lapatinib—Anorexia—Simvastatin—atherosclerosis	0.000628	0.00436	CcSEcCtD
Lapatinib—Dyspnoea—Lovastatin—atherosclerosis	0.000628	0.00436	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000627	0.00435	CcSEcCtD
Lapatinib—Insomnia—Ezetimibe—atherosclerosis	0.000625	0.00434	CcSEcCtD
Lapatinib—Arthralgia—Pravastatin—atherosclerosis	0.000621	0.00432	CcSEcCtD
Lapatinib—Myalgia—Pravastatin—atherosclerosis	0.000621	0.00432	CcSEcCtD
Lapatinib—Dyspepsia—Lovastatin—atherosclerosis	0.00062	0.00431	CcSEcCtD
Lapatinib—Dyspnoea—Ezetimibe—atherosclerosis	0.000616	0.00428	CcSEcCtD
Lapatinib—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000612	0.00425	CcSEcCtD
Lapatinib—Decreased appetite—Lovastatin—atherosclerosis	0.000612	0.00425	CcSEcCtD
Lapatinib—Dyspepsia—Ezetimibe—atherosclerosis	0.000608	0.00422	CcSEcCtD
Lapatinib—Fatigue—Lovastatin—atherosclerosis	0.000607	0.00422	CcSEcCtD
Lapatinib—Anaphylactic shock—Niacin—atherosclerosis	0.000605	0.0042	CcSEcCtD
Lapatinib—Constipation—Lovastatin—atherosclerosis	0.000602	0.00418	CcSEcCtD
Lapatinib—Decreased appetite—Ezetimibe—atherosclerosis	0.0006	0.00417	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.0006	0.00417	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000596	0.00414	CcSEcCtD
Lapatinib—Asthenia—Rosuvastatin—atherosclerosis	0.000596	0.00414	CcSEcCtD
Lapatinib—Insomnia—Simvastatin—atherosclerosis	0.000596	0.00414	CcSEcCtD
Lapatinib—Anaphylactic shock—Pravastatin—atherosclerosis	0.000595	0.00414	CcSEcCtD
Lapatinib—Fatigue—Ezetimibe—atherosclerosis	0.000595	0.00414	CcSEcCtD
Lapatinib—Infection—Pravastatin—atherosclerosis	0.000592	0.00411	CcSEcCtD
Lapatinib—Constipation—Ezetimibe—atherosclerosis	0.000591	0.0041	CcSEcCtD
Lapatinib—Pruritus—Rosuvastatin—atherosclerosis	0.000588	0.00408	CcSEcCtD
Lapatinib—Skin disorder—Niacin—atherosclerosis	0.000587	0.00408	CcSEcCtD
Lapatinib—Dyspnoea—Simvastatin—atherosclerosis	0.000587	0.00408	CcSEcCtD
Lapatinib—Dyspepsia—Simvastatin—atherosclerosis	0.00058	0.00403	CcSEcCtD
Lapatinib—Anorexia—Niacin—atherosclerosis	0.000576	0.00401	CcSEcCtD
Lapatinib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000576	0.004	CcSEcCtD
Lapatinib—Decreased appetite—Simvastatin—atherosclerosis	0.000573	0.00398	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000569	0.00395	CcSEcCtD
Lapatinib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000568	0.00395	CcSEcCtD
Lapatinib—Fatigue—Simvastatin—atherosclerosis	0.000568	0.00395	CcSEcCtD
Lapatinib—Anorexia—Pravastatin—atherosclerosis	0.000568	0.00394	CcSEcCtD
Lapatinib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000565	0.00392	CcSEcCtD
Lapatinib—Constipation—Simvastatin—atherosclerosis	0.000563	0.00391	CcSEcCtD
Lapatinib—Abdominal pain—Lovastatin—atherosclerosis	0.000557	0.00387	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000551	0.00383	CcSEcCtD
Lapatinib—Insomnia—Niacin—atherosclerosis	0.000547	0.0038	CcSEcCtD
Lapatinib—Abdominal pain—Ezetimibe—atherosclerosis	0.000546	0.00379	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000542	0.00377	CcSEcCtD
Lapatinib—Dyspnoea—Niacin—atherosclerosis	0.000539	0.00375	CcSEcCtD
Lapatinib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000539	0.00374	CcSEcCtD
Lapatinib—Insomnia—Pravastatin—atherosclerosis	0.000539	0.00374	CcSEcCtD
Lapatinib—Dyspepsia—Niacin—atherosclerosis	0.000532	0.0037	CcSEcCtD
Lapatinib—Dyspnoea—Pravastatin—atherosclerosis	0.000531	0.00369	CcSEcCtD
Lapatinib—Decreased appetite—Niacin—atherosclerosis	0.000526	0.00365	CcSEcCtD
Lapatinib—Dyspepsia—Pravastatin—atherosclerosis	0.000524	0.00364	CcSEcCtD
Lapatinib—Rash—Rosuvastatin—atherosclerosis	0.000524	0.00364	CcSEcCtD
Lapatinib—Dermatitis—Rosuvastatin—atherosclerosis	0.000523	0.00364	CcSEcCtD
Lapatinib—ABCB1—blood vessel—atherosclerosis	0.000522	0.0214	CbGeAlD
Lapatinib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000522	0.00363	CcSEcCtD
Lapatinib—Abdominal pain—Simvastatin—atherosclerosis	0.000521	0.00362	CcSEcCtD
Lapatinib—Headache—Rosuvastatin—atherosclerosis	0.000521	0.00362	CcSEcCtD
Lapatinib—Hypersensitivity—Lovastatin—atherosclerosis	0.000519	0.0036	CcSEcCtD
Lapatinib—Decreased appetite—Pravastatin—atherosclerosis	0.000518	0.0036	CcSEcCtD
Lapatinib—Fatigue—Pravastatin—atherosclerosis	0.000513	0.00357	CcSEcCtD
Lapatinib—Constipation—Pravastatin—atherosclerosis	0.000509	0.00354	CcSEcCtD
Lapatinib—Hypersensitivity—Ezetimibe—atherosclerosis	0.000509	0.00354	CcSEcCtD
Lapatinib—Asthenia—Lovastatin—atherosclerosis	0.000505	0.00351	CcSEcCtD
Lapatinib—Pruritus—Lovastatin—atherosclerosis	0.000498	0.00346	CcSEcCtD
Lapatinib—Asthenia—Ezetimibe—atherosclerosis	0.000496	0.00344	CcSEcCtD
Lapatinib—Gastrointestinal pain—Niacin—atherosclerosis	0.000495	0.00344	CcSEcCtD
Lapatinib—Nausea—Rosuvastatin—atherosclerosis	0.000494	0.00343	CcSEcCtD
Lapatinib—Pruritus—Ezetimibe—atherosclerosis	0.000489	0.00339	CcSEcCtD
Lapatinib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000487	0.00338	CcSEcCtD
Lapatinib—Hypersensitivity—Simvastatin—atherosclerosis	0.000485	0.00337	CcSEcCtD
Lapatinib—Diarrhoea—Lovastatin—atherosclerosis	0.000482	0.00335	CcSEcCtD
Lapatinib—Abdominal pain—Niacin—atherosclerosis	0.000478	0.00332	CcSEcCtD
Lapatinib—Asthenia—Simvastatin—atherosclerosis	0.000473	0.00328	CcSEcCtD
Lapatinib—Diarrhoea—Ezetimibe—atherosclerosis	0.000473	0.00328	CcSEcCtD
Lapatinib—Abdominal pain—Pravastatin—atherosclerosis	0.000471	0.00327	CcSEcCtD
Lapatinib—Pruritus—Simvastatin—atherosclerosis	0.000466	0.00324	CcSEcCtD
Lapatinib—Diarrhoea—Simvastatin—atherosclerosis	0.000451	0.00313	CcSEcCtD
Lapatinib—Vomiting—Lovastatin—atherosclerosis	0.000448	0.00311	CcSEcCtD
Lapatinib—Hypersensitivity—Niacin—atherosclerosis	0.000446	0.0031	CcSEcCtD
Lapatinib—Rash—Lovastatin—atherosclerosis	0.000444	0.00308	CcSEcCtD
Lapatinib—Dermatitis—Lovastatin—atherosclerosis	0.000444	0.00308	CcSEcCtD
Lapatinib—Headache—Lovastatin—atherosclerosis	0.000441	0.00306	CcSEcCtD
Lapatinib—Vomiting—Ezetimibe—atherosclerosis	0.000439	0.00305	CcSEcCtD
Lapatinib—Hypersensitivity—Pravastatin—atherosclerosis	0.000439	0.00305	CcSEcCtD
Lapatinib—Rash—Ezetimibe—atherosclerosis	0.000435	0.00303	CcSEcCtD
Lapatinib—Dermatitis—Ezetimibe—atherosclerosis	0.000435	0.00302	CcSEcCtD
Lapatinib—Asthenia—Niacin—atherosclerosis	0.000434	0.00301	CcSEcCtD
Lapatinib—Headache—Ezetimibe—atherosclerosis	0.000433	0.00301	CcSEcCtD
Lapatinib—Pruritus—Niacin—atherosclerosis	0.000428	0.00297	CcSEcCtD
Lapatinib—Asthenia—Pravastatin—atherosclerosis	0.000427	0.00297	CcSEcCtD
Lapatinib—Pruritus—Pravastatin—atherosclerosis	0.000421	0.00293	CcSEcCtD
Lapatinib—Vomiting—Simvastatin—atherosclerosis	0.000419	0.00291	CcSEcCtD
Lapatinib—Nausea—Lovastatin—atherosclerosis	0.000418	0.00291	CcSEcCtD
Lapatinib—Rash—Simvastatin—atherosclerosis	0.000415	0.00289	CcSEcCtD
Lapatinib—Dermatitis—Simvastatin—atherosclerosis	0.000415	0.00288	CcSEcCtD
Lapatinib—Diarrhoea—Niacin—atherosclerosis	0.000414	0.00287	CcSEcCtD
Lapatinib—Headache—Simvastatin—atherosclerosis	0.000413	0.00287	CcSEcCtD
Lapatinib—Nausea—Ezetimibe—atherosclerosis	0.00041	0.00285	CcSEcCtD
Lapatinib—Diarrhoea—Pravastatin—atherosclerosis	0.000407	0.00283	CcSEcCtD
Lapatinib—Nausea—Simvastatin—atherosclerosis	0.000391	0.00272	CcSEcCtD
Lapatinib—CYP3A5—adipose tissue—atherosclerosis	0.000387	0.0158	CbGeAlD
Lapatinib—Vomiting—Niacin—atherosclerosis	0.000385	0.00267	CcSEcCtD
Lapatinib—Rash—Niacin—atherosclerosis	0.000381	0.00265	CcSEcCtD
Lapatinib—Dermatitis—Niacin—atherosclerosis	0.000381	0.00265	CcSEcCtD
Lapatinib—Headache—Niacin—atherosclerosis	0.000379	0.00263	CcSEcCtD
Lapatinib—Vomiting—Pravastatin—atherosclerosis	0.000379	0.00263	CcSEcCtD
Lapatinib—Rash—Pravastatin—atherosclerosis	0.000375	0.00261	CcSEcCtD
Lapatinib—Dermatitis—Pravastatin—atherosclerosis	0.000375	0.00261	CcSEcCtD
Lapatinib—Headache—Pravastatin—atherosclerosis	0.000373	0.00259	CcSEcCtD
Lapatinib—Nausea—Niacin—atherosclerosis	0.000359	0.0025	CcSEcCtD
Lapatinib—Nausea—Pravastatin—atherosclerosis	0.000354	0.00246	CcSEcCtD
Lapatinib—CYP2C19—liver—atherosclerosis	0.000344	0.0141	CbGeAlD
Lapatinib—CYP2C8—liver—atherosclerosis	0.000301	0.0123	CbGeAlD
Lapatinib—CYP3A5—liver—atherosclerosis	0.000271	0.0111	CbGeAlD
Lapatinib—ABCB1—cardiovascular system—atherosclerosis	0.000233	0.00954	CbGeAlD
Lapatinib—ABCB1—adipose tissue—atherosclerosis	0.000206	0.00841	CbGeAlD
Lapatinib—CYP3A4—liver—atherosclerosis	0.000204	0.00834	CbGeAlD
Lapatinib—ABCB1—liver—atherosclerosis	0.000144	0.0059	CbGeAlD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.23e-05	6.85e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CXCL8—atherosclerosis	1.23e-05	6.84e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.23e-05	6.83e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PLA2G1B—atherosclerosis	1.23e-05	6.82e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—HMGCR—atherosclerosis	1.22e-05	6.79e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NAMPT—atherosclerosis	1.22e-05	6.79e-05	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	1.22e-05	6.76e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ALOX5—atherosclerosis	1.22e-05	6.75e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—MAPK3—atherosclerosis	1.22e-05	6.75e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.22e-05	6.75e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—LIPC—atherosclerosis	1.22e-05	6.74e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CXCL8—atherosclerosis	1.22e-05	6.74e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—APOC3—atherosclerosis	1.21e-05	6.7e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SOCS3—atherosclerosis	1.2e-05	6.66e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—LDLR—atherosclerosis	1.2e-05	6.66e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NOS2—atherosclerosis	1.19e-05	6.62e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ALOX5—atherosclerosis	1.19e-05	6.59e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CETP—atherosclerosis	1.17e-05	6.51e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MMP3—atherosclerosis	1.16e-05	6.44e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IGF2—atherosclerosis	1.16e-05	6.41e-05	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.14e-05	6.34e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.12e-05	6.24e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—SCARB1—atherosclerosis	1.12e-05	6.23e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—APOB—atherosclerosis	1.12e-05	6.22e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MMP9—atherosclerosis	1.12e-05	6.19e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NFKB1—atherosclerosis	1.1e-05	6.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—EDN1—atherosclerosis	1.1e-05	6.12e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MMP9—atherosclerosis	1.1e-05	6.1e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCL5—atherosclerosis	1.1e-05	6.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—INS—atherosclerosis	1.09e-05	6.07e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.09e-05	6.07e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NAMPT—atherosclerosis	1.09e-05	6.06e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ABCA1—atherosclerosis	1.09e-05	6.05e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NFKB1—atherosclerosis	1.09e-05	6.03e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.09e-05	6.02e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MAPK8—atherosclerosis	1.09e-05	6.02e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—LIPC—atherosclerosis	1.09e-05	6.02e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ABCG1—atherosclerosis	1.08e-05	6.01e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—APOC3—atherosclerosis	1.08e-05	5.98e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL6—atherosclerosis	1.07e-05	5.95e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—LDLR—atherosclerosis	1.07e-05	5.95e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—LPL—atherosclerosis	1.07e-05	5.94e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MAPK8—atherosclerosis	1.07e-05	5.93e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NAMPT—atherosclerosis	1.07e-05	5.91e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—HMGCR—atherosclerosis	1.06e-05	5.88e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—LIPC—atherosclerosis	1.06e-05	5.87e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL6—atherosclerosis	1.06e-05	5.86e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—APOC3—atherosclerosis	1.05e-05	5.84e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CETP—atherosclerosis	1.05e-05	5.81e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—LDLR—atherosclerosis	1.05e-05	5.8e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PRKCG—atherosclerosis	1.04e-05	5.77e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CETP—atherosclerosis	1.02e-05	5.67e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—FABP4—atherosclerosis	1.02e-05	5.65e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—LCAT—atherosclerosis	1.02e-05	5.65e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SPP1—atherosclerosis	1.01e-05	5.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CXCL8—atherosclerosis	1.01e-05	5.6e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—IL6—atherosclerosis	1.01e-05	5.59e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—SERPINE1—atherosclerosis	1.01e-05	5.58e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	1e-05	5.56e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—SCARB1—atherosclerosis	1e-05	5.56e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—VEGFA—atherosclerosis	1e-05	5.56e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—APOA4—atherosclerosis	1e-05	5.55e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—STAT3—atherosclerosis	9.92e-06	5.5e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IFNG—atherosclerosis	9.92e-06	5.5e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—IL6—atherosclerosis	9.9e-06	5.49e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—AKT1—atherosclerosis	9.89e-06	5.49e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—VEGFA—atherosclerosis	9.87e-06	5.47e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP7A1—atherosclerosis	9.83e-06	5.45e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—SCARB1—atherosclerosis	9.79e-06	5.43e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—STAT3—atherosclerosis	9.77e-06	5.42e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	9.76e-06	5.41e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—IL6—atherosclerosis	9.75e-06	5.41e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—AKT1—atherosclerosis	9.74e-06	5.4e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NOS3—atherosclerosis	9.6e-06	5.33e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	9.57e-06	5.31e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MAPK3—atherosclerosis	9.48e-06	5.26e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—HMGCR—atherosclerosis	9.47e-06	5.25e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ABCA1—atherosclerosis	9.45e-06	5.24e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PDGFB—atherosclerosis	9.38e-06	5.2e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—HMOX1—atherosclerosis	9.37e-06	5.19e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MAPK3—atherosclerosis	9.34e-06	5.18e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—AKT1—atherosclerosis	9.29e-06	5.15e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—HMGCR—atherosclerosis	9.24e-06	5.13e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TGFB1—atherosclerosis	9.2e-06	5.1e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AGT—atherosclerosis	9.16e-06	5.08e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—AKT1—atherosclerosis	9.13e-06	5.06e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP27A1—atherosclerosis	9.08e-06	5.04e-05	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	9.06e-06	5.03e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TGFB1—atherosclerosis	9.06e-06	5.02e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—AKT1—atherosclerosis	8.99e-06	4.99e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—LEP—atherosclerosis	8.98e-06	4.98e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—APOE—atherosclerosis	8.98e-06	4.98e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—APOB—atherosclerosis	8.97e-06	4.98e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—IL6—atherosclerosis	8.9e-06	4.93e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CAV1—atherosclerosis	8.89e-06	4.93e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—APOA1—atherosclerosis	8.87e-06	4.92e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL1B—atherosclerosis	8.85e-06	4.91e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTGS2—atherosclerosis	8.78e-06	4.87e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GSTM1—atherosclerosis	8.73e-06	4.84e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	8.61e-06	4.78e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—APOA2—atherosclerosis	8.61e-06	4.78e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ALOX15—atherosclerosis	8.61e-06	4.78e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	8.61e-06	4.78e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ESR1—atherosclerosis	8.57e-06	4.75e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—LPL—atherosclerosis	8.57e-06	4.75e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	8.54e-06	4.74e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ABCG5—atherosclerosis	8.51e-06	4.72e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—F2—atherosclerosis	8.46e-06	4.69e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ABCA1—atherosclerosis	8.44e-06	4.68e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GPX1—atherosclerosis	8.36e-06	4.64e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NFKB1—atherosclerosis	8.26e-06	4.58e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ABCA1—atherosclerosis	8.24e-06	4.57e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—LPA—atherosclerosis	8.21e-06	4.56e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—AKT1—atherosclerosis	8.21e-06	4.55e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CD36—atherosclerosis	8.14e-06	4.51e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MAPK8—atherosclerosis	8.11e-06	4.5e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—HMOX1—atherosclerosis	8.11e-06	4.5e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CG—atherosclerosis	8.1e-06	4.49e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—BGN—atherosclerosis	7.96e-06	4.41e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—AKT1—atherosclerosis	7.88e-06	4.37e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—APOA5—atherosclerosis	7.88e-06	4.37e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—APOB—atherosclerosis	7.77e-06	4.31e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—MAPK3—atherosclerosis	7.76e-06	4.3e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—MTHFR—atherosclerosis	7.71e-06	4.28e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—INS—atherosclerosis	7.67e-06	4.25e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	7.58e-06	4.2e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PPARA—atherosclerosis	7.57e-06	4.2e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GSTM1—atherosclerosis	7.56e-06	4.19e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCL2—atherosclerosis	7.54e-06	4.18e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—LPL—atherosclerosis	7.42e-06	4.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—STAT3—atherosclerosis	7.42e-06	4.11e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IGF1—atherosclerosis	7.42e-06	4.11e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—AGT—atherosclerosis	7.33e-06	4.06e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ALOX5—atherosclerosis	7.32e-06	4.06e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—HMOX1—atherosclerosis	7.24e-06	4.02e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GPX1—atherosclerosis	7.24e-06	4.01e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—APOE—atherosclerosis	7.18e-06	3.98e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CAV1—atherosclerosis	7.11e-06	3.95e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—APOA1—atherosclerosis	7.1e-06	3.94e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MAPK3—atherosclerosis	7.09e-06	3.93e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—HMOX1—atherosclerosis	7.07e-06	3.92e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CD36—atherosclerosis	7.05e-06	3.91e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SERPINE1—atherosclerosis	7.04e-06	3.91e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—APOB—atherosclerosis	6.94e-06	3.85e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL6—atherosclerosis	6.93e-06	3.84e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—STAT3—atherosclerosis	6.85e-06	3.8e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL6—atherosclerosis	6.83e-06	3.79e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—APOB—atherosclerosis	6.77e-06	3.75e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GSTM1—atherosclerosis	6.75e-06	3.74e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NOS3—atherosclerosis	6.72e-06	3.73e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—MTHFR—atherosclerosis	6.68e-06	3.71e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—LPL—atherosclerosis	6.62e-06	3.67e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GSTM1—atherosclerosis	6.58e-06	3.65e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NAMPT—atherosclerosis	6.57e-06	3.64e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PPARA—atherosclerosis	6.55e-06	3.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MAPK3—atherosclerosis	6.54e-06	3.63e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—LIPC—atherosclerosis	6.53e-06	3.62e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—APOC3—atherosclerosis	6.49e-06	3.6e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CG—atherosclerosis	6.48e-06	3.59e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—LPL—atherosclerosis	6.46e-06	3.59e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GPX1—atherosclerosis	6.46e-06	3.58e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—LDLR—atherosclerosis	6.45e-06	3.58e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—AKT1—atherosclerosis	6.39e-06	3.55e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—TGFB1—atherosclerosis	6.35e-06	3.52e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—AGT—atherosclerosis	6.35e-06	3.52e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GPX1—atherosclerosis	6.31e-06	3.5e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—AKT1—atherosclerosis	6.3e-06	3.49e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CETP—atherosclerosis	6.3e-06	3.49e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CD36—atherosclerosis	6.29e-06	3.49e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PPARG—atherosclerosis	6.25e-06	3.47e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—APOE—atherosclerosis	6.22e-06	3.45e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CAV1—atherosclerosis	6.16e-06	3.42e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—APOA1—atherosclerosis	6.15e-06	3.41e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CD36—atherosclerosis	6.14e-06	3.41e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—INS—atherosclerosis	6.13e-06	3.4e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SCARB1—atherosclerosis	6.03e-06	3.34e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCL8—atherosclerosis	5.96e-06	3.31e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—MTHFR—atherosclerosis	5.96e-06	3.31e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PPARA—atherosclerosis	5.85e-06	3.24e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—MTHFR—atherosclerosis	5.82e-06	3.23e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PPARA—atherosclerosis	5.71e-06	3.17e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HMGCR—atherosclerosis	5.69e-06	3.16e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL6—atherosclerosis	5.67e-06	3.15e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—AGT—atherosclerosis	5.67e-06	3.14e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ALB—atherosclerosis	5.62e-06	3.12e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CG—atherosclerosis	5.61e-06	3.11e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—APOE—atherosclerosis	5.55e-06	3.08e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—AGT—atherosclerosis	5.53e-06	3.07e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CAV1—atherosclerosis	5.5e-06	3.05e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—APOA1—atherosclerosis	5.49e-06	3.04e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—APOE—atherosclerosis	5.42e-06	3.01e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PPARG—atherosclerosis	5.42e-06	3e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MMP9—atherosclerosis	5.39e-06	2.99e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—NOS3—atherosclerosis	5.38e-06	2.98e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CAV1—atherosclerosis	5.37e-06	2.98e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—APOA1—atherosclerosis	5.36e-06	2.97e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NFKB1—atherosclerosis	5.34e-06	2.96e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—INS—atherosclerosis	5.31e-06	2.95e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MAPK8—atherosclerosis	5.25e-06	2.91e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—AKT1—atherosclerosis	5.23e-06	2.9e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL6—atherosclerosis	5.18e-06	2.87e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ABCA1—atherosclerosis	5.07e-06	2.81e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CG—atherosclerosis	5.01e-06	2.78e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTGS2—atherosclerosis	4.92e-06	2.73e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CG—atherosclerosis	4.89e-06	2.71e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ALB—atherosclerosis	4.87e-06	2.7e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—VEGFA—atherosclerosis	4.84e-06	2.69e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PPARG—atherosclerosis	4.83e-06	2.68e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—STAT3—atherosclerosis	4.8e-06	2.66e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—IL6—atherosclerosis	4.78e-06	2.65e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—AKT1—atherosclerosis	4.78e-06	2.65e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—INS—atherosclerosis	4.74e-06	2.63e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PPARG—atherosclerosis	4.72e-06	2.62e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NOS3—atherosclerosis	4.66e-06	2.58e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—INS—atherosclerosis	4.63e-06	2.57e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MAPK3—atherosclerosis	4.58e-06	2.54e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TGFB1—atherosclerosis	4.45e-06	2.47e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—AKT1—atherosclerosis	4.41e-06	2.45e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.35e-06	2.41e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ALB—atherosclerosis	4.35e-06	2.41e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTGS2—atherosclerosis	4.26e-06	2.36e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ALB—atherosclerosis	4.24e-06	2.35e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—APOB—atherosclerosis	4.17e-06	2.31e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NOS3—atherosclerosis	4.16e-06	2.31e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NOS3—atherosclerosis	4.06e-06	2.25e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTM1—atherosclerosis	4.06e-06	2.25e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—LPL—atherosclerosis	3.98e-06	2.21e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GPX1—atherosclerosis	3.89e-06	2.15e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTGS2—atherosclerosis	3.8e-06	2.11e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CD36—atherosclerosis	3.78e-06	2.1e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTGS2—atherosclerosis	3.71e-06	2.06e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.59e-06	1.99e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PPARA—atherosclerosis	3.52e-06	1.95e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AGT—atherosclerosis	3.41e-06	1.89e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL6—atherosclerosis	3.35e-06	1.86e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—APOE—atherosclerosis	3.34e-06	1.85e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CAV1—atherosclerosis	3.31e-06	1.83e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—APOA1—atherosclerosis	3.3e-06	1.83e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AKT1—atherosclerosis	3.09e-06	1.71e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	3.01e-06	1.67e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PPARG—atherosclerosis	2.91e-06	1.61e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—INS—atherosclerosis	2.85e-06	1.58e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ALB—atherosclerosis	2.61e-06	1.45e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NOS3—atherosclerosis	2.5e-06	1.39e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—AKT1—atherosclerosis	2.47e-06	1.37e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.29e-06	1.27e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—AKT1—atherosclerosis	2.14e-06	1.19e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—AKT1—atherosclerosis	1.91e-06	1.06e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—AKT1—atherosclerosis	1.87e-06	1.03e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AKT1—atherosclerosis	1.15e-06	6.38e-06	CbGpPWpGaD
